MedTrace Logo

An Efficacy/Safety Study of Perampanel for Reducing Essential Tremor

NCT02668146 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2016-09-12

No results posted yet for this study

Summary

Obtain information on whether the medication Perampanel reduces tremor in people with essential tremor and is well-tolerated.

Conditions

Interventions

DRUG

Perampanel

Study drug will be administered to study subjects

DRUG

Placebo

Placebo will be administered to study subjects

Sponsors & Collaborators

  • VA Greater Los Angeles Healthcare System

    lead FED

Principal Investigators

  • Charles A Handforth, M.D. · VHAGLAHS

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2017-03-31
Completion
2017-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02668146 on ClinicalTrials.gov